Progress report: growth hormone in skeletal dysplasia

Area of Science:

• Pediatric Endocrinology
• Genetics
• Skeletal Biology

Background:

• Short stature is a common concern in skeletal dysplasias.
• Growth hormone (GH) is a standard treatment for idiopathic short stature.
• GH concentrations are typically normal in individuals with skeletal dysplasia.

Purpose of the Study:

• To evaluate the efficacy of growth hormone treatment in children with skeletal dysplasia.
• To determine if growth hormone therapy improves final height in skeletal dysplasia.
• To review current evidence on growth hormone's impact on growth velocity and final height.

Main Methods:

• Review of short-term clinical trials involving growth hormone therapy.
• Analysis of data from studies on specific skeletal dysplasias like achondroplasia and hypochondroplasia.
• Examination of long-term outcomes in patients with Turner syndrome and skeletal dysplasia.

Main Results:

• Growth hormone treatment increases growth velocity in most skeletal dysplasias.
• Sustained growth velocity increases observed for up to 4 years in achondroplasia and 6 years in hypochondroplasia.
• Confirmed final height increase with growth hormone treatment is only documented in skeletal dysplasia associated with Turner syndrome.

Conclusions:

• Growth hormone is not a universally logical treatment for short stature in skeletal dysplasia due to normal endogenous GH levels.
• While growth velocity improves, final height benefits are primarily seen in Turner syndrome.
• Further research into the underlying defects of skeletal dysplasia is crucial for improved diagnostic and therapeutic strategies.